Oviva Therapeutics, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Oviva Therapeutics, Inc. - overview
Established
2021
Location
New York, NY, US
Primary Industry
Biotechnology
About
Founded in 2021 and based in New York, US, Oviva Therapeutics, Inc. is a majority-owned pipeline company (PipeCo) of Cambrian Biopharma, a multi-asset longevity biotech company developing therapeutics to first cure diseases and then develop treatments to prevent conditions from occurring. In May 2022, Oviva Therapeutics, Inc. raised USD 11.
5 million in Seed funding from Cambrian Biopharma. Daisy Robinton (CEO), David Pépin, and Patricia K. Donahoe are the co-founders of the company. The company is developing a drug that targets folliculogenesis, the process by which ovarian follicles, each containing a single egg, mature and eventually ovulate.
The firm addresses women’s health by expanding funding, research, and clinical development. The organization plans to use the May 2022 funding to develop treatments to improve the health span, which is the period during which women can live in good health.
Current Investors
Cambrian Biopharma
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.ovivatx.com
Company Stage
Angel & Seed
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.